Rapid purification and direct microassay of calbindin9kDa utilizing its solubility in perchloric acid.
Detection of GPCR mRNA Expression in Major Cells Through qPCR, Microarrays, and RNA-Sequencing
A workflow is described for assaying the expression of G protein-coupled receptors (GPCRs) in cultured cells, utilizing a mix of strategies that assess GPCR mRNAs. Starting from the isolation of cDNA and preparation of mRNA, we offer protocols for designing and testing qPCR primers, assaying mRNA expression utilizing qPCR and high-throughput evaluation of GPCR mRNA expression by way of TaqMan qPCR-based, GPCR-selective arrays.
We additionally present a workflow for evaluation of expression from RNA-sequencing (RNA-seq) assays, which could be queried to yield expression of GPCRs and associated genes in samples of curiosity, in addition to to check adjustments in expression between teams, reminiscent of in cells handled with medication or from wholesome and diseased topics.
We place precedence on optimized protocols that distinguish sign from noise, as GPCR mRNAs are sometimes current in low abundance, necessitating methods that maximize sensitivity whereas minimizing noise. These strategies might also be relevant for assessing the expression of members of households of different low abundance genes by way of high-throughput analyses of mRNAs, adopted by unbiased affirmation and validation of outcomes by way of qPCR.
Responsive Hydrogel Binding Matrix for Twin Sign Amplification in Fluorescence Affinity Biosensors and Peptide Microarrays
A mixed strategy to sign enhancement in fluorescence affinity biosensors and assays is reported. It’s based mostly on the compaction of particularly captured goal molecules on the sensor floor adopted by optical probing with a tightly confined floor plasmon (SP) subject. This idea is utilized through the use of a thermoresponsive hydrogel (HG) binding matrix that’s ready from a terpolymer derived from poly(N-isopropylacrylamide) (pNIPAAm) and hooked up to a metallic sensor floor. Epi-illumination fluorescence and SP-enhanced whole inner reflection fluorescence readouts of affinity binding occasions are carried out to spatially interrogate the fluorescent sign within the course parallel and perpendicular to the sensor floor.
The pNIPAAm-based HG binding matrix is organized in arrays of sensing spots and employed for the particular detection of human IgG antibodies in opposition to the Epstein-Barr virus (EBV). The detection is carried out in diluted human plasma or with remoted human IgG through the use of a set of peptide ligands mapping the epitope of the EBV nuclear antigen. Alkyne-terminated peptides have been covalently coupled to the pNIPAAm-based HG carrying azide moieties. Importantly, utilizing such low-molecular-weight ligands allowed preserving the thermoresponsive properties of the pNIPAAm-based structure, which was not doable for amine coupling of normal antibodies which have the next molecular weight.
Microarray evaluation reveals an inflammatory transcriptomic signature in peripheral blood for sciatica
Background: Though the pathology of sciatica has been studied extensively, the transcriptional adjustments within the peripheral blood brought on by sciatica haven’t been characterised. This examine aimed to characterize the peripheral blood transcriptomic signature for sciatica.
Strategies: We used a microarray to determine differentially expressed genes within the peripheral blood of sufferers with sciatica in contrast with that of wholesome controls, carried out a useful evaluation to disclose the peripheral blood transcriptomic signature for sciatica, and performed a community evaluation to determine key genes that contribute to the noticed transcriptional adjustments. The expression ranges of those key genes have been assessed by qRT-PCR.
Outcomes: We discovered that 153 genes have been differentially expressed within the peripheral blood of sufferers with sciatica in contrast with that of wholesome controls, and 131 and 22 of those have been upregulated and downregulated, respectively. A useful evaluation revealed that these differentially expressed genes (DEGs) have been strongly enriched for the inflammatory response or immunity. The community evaluation revealed {that a} group of genes, most of that are associated to the inflammatory response, performed a key function within the dysregulation of those DEGs. These key genes are Toll-like receptor 4, matrix metallopeptidase 9, myeloperoxidase, cathelicidin antimicrobial peptide, resistin and Toll-like receptor 5, and a qRT-PCR evaluation validated the upper transcript ranges of those key genes within the peripheral blood of sufferers with sciatica than in that of wholesome controls.
Conclusion: We revealed inflammatory traits that function a peripheral blood transcriptomic signature for sciatica and recognized genes which can be important for mRNA dysregulation within the peripheral blood of sufferers with sciatica.
Metabolic utilization of human osteoblast cell line hFOB 1.19 beneath normoxic and hypoxic situations: A phenotypic microarray evaluation
At the moment, researchers perceive that bone cells expertise hypoxia throughout bone harm or fracture. Such stress situation exerts impact on bone regeneration and restore. Nonetheless, there’s restricted data on the metabolites and metabolism adjustments that happen in osteoblast cells after they bear inherent regeneration and restore beneath hypoxia. This manuscript describes the usage of Phenotype MicroArrays to watch the response of human osteoblast cells beneath normoxic and hypoxic situations when it comes to cell development and utilization of metabolites.
The human osteoblast cultured beneath these two completely different oxygen concentrations confirmed completely different development curve and utilization of metabolites, suggesting oxygen ranges play a task in bone restore and therapeutic. We’ve got deduced the principle metabolites for osteoblast cells to provide vitality beneath normoxic and hypoxic situations. The brand new findings on this analysis assist researchers to grasp how hypoxia can affect utilization of metabolites in osteoblast cells, which function vital data to enhance strategies for bone regeneration.
GEOlimma: differential expression evaluation and have choice utilizing pre-existing microarray information
Background: Differential expression and have choice analyses are important steps for the event of correct diagnostic/prognostic classifiers of difficult human ailments utilizing transcriptomics information. These steps are significantly difficult as a result of curse of dimensionality and the presence of technical and organic noise. A promising technique for overcoming these challenges is the incorporation of pre-existing transcriptomics information within the identification of differentially expressed (DE) genes. This strategy has the potential to enhance the standard of chosen genes, improve classification efficiency, and improve organic interpretability. Whereas a lot of strategies have been developed that use pre-existing information for differential expression evaluation, present strategies don’t leverage the identities of experimental situations to create a strong metric for figuring out DE genes.
Outcomes: On this examine, we suggest a novel differential expression and have choice method-GEOlimma-which combines pre-existing microarray information from the Gene Expression Omnibus (GEO) with the widely-applied Limma methodology for differential expression evaluation.
We first quantify differential gene expression throughout 2481 pairwise comparisons from 602 curated GEO Datasets, and we convert differential expression frequencies to DE prior chances. Genes with excessive DE prior chances present enrichment in cell development and dying, sign transduction, and cancer-related organic pathways, whereas genes with low prior chances have been enriched in sensory system pathways.
We then utilized GEOlimma to 4 differential expression comparisons inside two human illness datasets and carried out differential expression, function choice, and supervised classification analyses. Our outcomes counsel that use of GEOlimma offers higher experimental energy to detect DE genes in comparison with Limma, resulting from its elevated efficient pattern dimension. Moreover, in a supervised classification evaluation utilizing GEOlimma as a function choice methodology, we noticed related or higher classification efficiency than Limma given small, noisy subsets of an bronchial asthma dataset.
Conclusions: Our outcomes exhibit that GEOlimma is a simpler methodology for differential gene expression and have choice analyses in comparison with the usual Limma methodology. Because of its concentrate on gene-level differential expression, GEOlimma additionally has the potential to be utilized to different high-throughput organic datasets.
 Anti-Human LEC/NCC-4 Antibody | |||
| 102-P51G | ReliaTech | 100 µg | EUR 245.7 |
Description: LEC or NCC-4 is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines. | |||
) Recombinant Human LEC (CCL16) | |||
| Z100325 | ABM | 25 µg | EUR 235 |
Description: CCL16 is a CC chemokine that specifically attracts lymphocytes, dendritic cells, and monocytes; increases their adhesive properties and has myelosuppressive activity. It is constitutively expressed in liver and is increased by interleukin 10 (IL-10) in activated monocytes. CCL16 is present in human plasma suggesting that it may be active outside hepatic tissue. CCR1, CCR2, CCR5, and CCR8 are the functional receptors of this chemokine. | |||
) Recombinant Human LEC (CCL16) | |||
| Z100329 | ABM | 1.0 mg | EUR 3900 |
Description: CCL16 is a CC chemokine that specifically attracts lymphocytes, dendritic cells, and monocytes; increases their adhesive properties and has myelosuppressive activity. It is constitutively expressed in liver and is increased by interleukin 10 (IL-10) in activated monocytes. CCL16 is present in human plasma suggesting that it may be active outside hepatic tissue. CCR1, CCR2, CCR5, and CCR8 are the functional receptors of this chemokine. | |||
 Anti-Human LEC Goat Polyclonal Antibody | |||
| TA328365 | Origene Technologies GmbH | 100 µg | Ask for price |
 Human LEC/CCL16 Antibody Pair Set | |||
| ABPR-ZB293 | Creative Diagnostics | 5 plates, 15 plates | Ask for price |
Description: Quantitative determination of Human LEC/CCL16 | |||
 LEC antibody | |||
| 10R-L115A | Fitzgerald | 500 ug | EUR 240 |
Description: Mouse monoclonal LEC antibody | |||
LEC antibody | |||
| 70R-LG003 | Fitzgerald | 50 ug | EUR 312 |
Description: Affinity purified Goat polyclonal LEC antibody | |||
 LEC/NCC-4 Human Recombinant | |||
| rAP-0241 | Angio Proteomie | Inquiry | Ask for price |
 Protein) Recombinant Human LEC (CCL16) Protein | |||
| PROTO15467-1 | BosterBio | 20ug | EUR 380.4 |
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines. | |||
 Biotinylated Anti-Human LEC Goat Polyclonal Antibody | |||
| TA328364 | Origene Technologies GmbH | 50 µg | Ask for price |
 Human LEC Recombinant Protein Lyophilized | |||
| IHULECRLY5UG | Innovative research | each | EUR 341 |
Description: Human LEC Recombinant Protein Lyophilized | |||
) Recombinant Human LEC/NCC-4 (CCL16) | |||
| 7-01792 | CHI Scientific | 5µg | Ask for price |
Recombinant Human LEC/NCC-4 (CCL16) | |||
| 7-01793 | CHI Scientific | 20µg | Ask for price |
Recombinant Human LEC/NCC-4 (CCL16) | |||
| 7-01794 | CHI Scientific | 1mg | Ask for price |
) Recombinant Human LEC/NCC-4 (CCL16) | |||
| HECCP-1601 | Cyagen | 5ug | Ask for price |
 LEC protein | |||
| 30R-AL013 | Fitzgerald | 20 ug | EUR 312 |
Description: Purified recombinant Human LEC protein | |||
 Antibody) LEC Chemokine(LEC66) Antibody | |||
| BNC940066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF594 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC940066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF594 conjugate, Concentration: 0.1mg/mL | |||
 Antibody) LEC Chemokine(LEC67) Antibody | |||
| BNC940067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF594 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC940067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF594 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCH0066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCH0066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCH0067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCH0067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNUM0066-50 | Biotium | 50uL | EUR 474 |
Description: Primary antibody against LEC Chemokine(LEC66), 1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNUM0067-50 | Biotium | 50uL | EUR 474 |
Description: Primary antibody against LEC Chemokine(LEC67), 1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC700066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF770 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC700066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF770 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC700067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF770 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC700067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF770 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC800066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF680 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC800066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF680 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC800067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF680 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC800067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF680 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC810066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF680R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC810066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF680R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC810067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF680R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC810067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF680R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC880066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF488A conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC880066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF488A conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC880067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF488A conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC880067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF488A conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC550066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF555 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC550066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF555 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC550067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF555 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC550067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF555 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC610066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF660R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC610066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF660R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC610067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF660R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC610067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF660R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC430066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF543 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC430066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF543 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC430067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF543 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC430067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF543 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC470066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF647 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC470066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF647 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC470067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF647 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC470067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF647 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC680066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF568 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC680066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF568 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC680067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF568 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC680067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF568 conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC050066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF405M conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC050066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF405M conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC050067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF405M conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC050067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF405M conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC040066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF405S conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC040066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF405S conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC040067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF405S conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC040067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF405S conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC400066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF640R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNC400066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), CF640R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC400067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF640R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNC400067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), CF640R conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCA0066-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against LEC Chemokine(LEC66), APC conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCA0067-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against LEC Chemokine(LEC67), APC conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCAP0066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCAP0066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCAP0067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCAP0067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCB0066-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Biotin conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCB0066-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Biotin conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCB0067-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against LEC Chemokine(LEC67), Biotin conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCB0067-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against LEC Chemokine(LEC67), Biotin conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCP0066-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against LEC Chemokine(LEC66), PerCP conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCP0067-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against LEC Chemokine(LEC67), PerCP conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNCR0066-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against LEC Chemokine(LEC66), RPE conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC67) Antibody | |||
| BNCR0067-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against LEC Chemokine(LEC67), RPE conjugate, Concentration: 0.1mg/mL | |||
LEC Chemokine(LEC66) Antibody | |||
| BNUB0066-100 | Biotium | 100uL | EUR 250.8 |
Description: Primary antibody against LEC Chemokine(LEC66), Concentration: 0.2mg/mL | |||
